Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2015

Open Access 01-12-2015 | Research article

Ischemic heart disease among subjects with and without chronic obstructive pulmonary disease – ECG-findings in a population-based cohort study

Authors: Ulf Nilsson, Bengt Johansson, Berne Eriksson, Anders Blomberg, Bo Lundbäck, Anne Lindberg

Published in: BMC Pulmonary Medicine | Issue 1/2015

Login to get access

Abstract

Background

Cardiovascular comorbidity in COPD is common and contributes to increased mortality. A few population-based studies indicate that ischemic electrocardiogram (ECG)-changes are more prevalent in COPD, while others do not. The aim of the present study was to estimate the presence of ischemic heart disease (IHD) in a population-based COPD-cohort in comparison with subjects without COPD.

Methods

All subjects with obstructive lung function (COPD, n = 993) were identified together with age- and sex-matched controls (non-COPD, n = 993) from population-based cohorts examined in 2002–04. In 2005, data from structured interview, spirometry and ECG were collected from 1625 subjects. COPD was classified into GOLD 1–4 after post-bronchodilator spirometry. Ischemic ECG-changes, based on Minnesota-coding, were classified according to the Whitehall criteria into probable and possible IHD.

Results

Self-reported IHD was equally common in COPD and non-COPD, and so were probable and possible ischemic ECG-changes according to Whitehall. After excluding subjects with restrictive spirometric pattern from the non-COPD-group, similar comparison with regard to presence of IHD performed between those with COPD and those with normal lung-function did neither show any differences. There was a significant association between self-reported IHD (p = 0.007) as well as probable ischemic ECG-changes (p = 0.042), and increasing GOLD stage. In COPD there was a significant association between level of FEV1 percent of predicted and self-reported as well as probable ischemic ECG-changes, and this association persisted for self-reported IHD also after adjustment for sex and age.

Conclusion

In this population-based study, self-reported IHD and probable ischemic ECG-changes were associated with COPD disease severity assessed by spirometry.
Appendix
Available only for authorised users
Literature
1.
Lindberg A, Bjerg A, Bjerg-Bäcklund A, Rönmark E, Larsson LG, Lundbäck B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2006;100(2):264–72.CrossRefPubMed
2.
Soriano JB, Ancochea J, Miravitlles M, García-Río F, Duran-Tauleria E, Muñoz L, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007. Eur Respir J. 2010;36(4):758–65.CrossRefPubMed
3.
Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med. 2010;170(6):560–5.CrossRefPubMed
4.
Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–49.PubMedCentralCrossRefPubMed
5.
WHO: GLOBAL STATUS REPORTon noncommunicable diseases 2014. In.; 2014.
6.
Lindberg A, Larsson LG, Muellerova H, Ronmark E, Lundback B. Up-to-date on mortality in COPD - report from the OLIN COPD study. BMC Pulm Med. 2012;12:1.PubMedCentralCrossRefPubMed
7.
Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, et al. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5(4):235–56.CrossRefPubMed
8.
Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. In: Lancet. 379th ed. England: 2012 Elsevier Ltd; 2012. p. 1341–51.
9.
Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, et al. The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease. Int J Cardiol. 2010;145(2):172–6.CrossRefPubMed
10.
Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. European respiratory review : an official journal of the European Respiratory Society. 2013;22(130):454–75.CrossRef
11.
Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991–1999. COPD. 2005;2(1):35–41.CrossRefPubMed
12.
de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Bellon-Cano JM, Ancochea-Bermudez J, Calle-Rubio M, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch Bronconeumol. 2008;44(5):233–8.PubMed
13.
Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99(5):636–41.CrossRefPubMed
14.
Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750–7.CrossRefPubMed
15.
Engstrom G, Hedblad B, Janzon L. Reduced lung function predicts increased fatality in future cardiac events. A population-based study. J Intern Med. 2006;260(6):560–7.CrossRefPubMed
16.
Campo G, Pavasini R, Malagu M, Mascetti S, Biscaglia S, Ceconi C, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–57.CrossRefPubMed
17.
Lindberg A, Lundbäck B. The Obstructive Lung Disease in Northern Sweden Chronic Obstructive Pulmonary Disease Study: design, the first year participation and mortality. Clin Respir J. 2008;2 Suppl 1:64–71.CrossRefPubMed
18.
Jyrki-Tapani K, Sovijarvi A, Lundback B. Chronic obstructive pulmonary disease in Finland: prevalence and risk factors. COPD. 2005;2(3):331–9.CrossRefPubMed
19.
Lundback B, Stjernberg N, Rosenhall L, Lindstrom M, Jonsson E, Andersson S. Methacholine reactivity and asthma. Report from the Northern Sweden Obstructive Lung Disease Project. Allergy. 1993;48(2):117–24.CrossRefPubMed
20.
Lundback B, Stjernberg N, Nystrom L, Forsberg B, Lindstrom M, Lundback K, et al. Epidemiology of respiratory symptoms, lung function and important determinants. Report from the Obstructive Lung Disease in Northern Sweden Project. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 1994;75(2):116–26.CrossRef
21.
Lundback B, Ronmark E, Jonsson E, Larsson K, Sandstrom T. Incidence of physician-diagnosed asthma in adults--a real incidence or a result of increased awareness? Report from The Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2001;95(8):685–92.CrossRefPubMed
22.
Reid DD, Hamilton PJ, McCartney P, Rose G, Jarrett RJ, Keen H. Smoking and other risk factors for coronary heart-disease in British civil servants. Lancet. 1976;2(7993):979–84.CrossRefPubMed
23.
American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med. 1995;152(3):1107–1136.CrossRef
24.
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available from: [http://​www.​goldcopd.​org].
25.
Backman H, Lindberg A, Sovijärvi A, Larsson K, Lundbäck B, Rönmark E. Evaluation of the global lung function initiative 2012 reference values for spirometry in a Swedish population sample. BMC Pulm Med. 2015;15(1):26.PubMedCentralCrossRefPubMed
26.
Backman H, Lindberg A, Odén A, Ekerljung L, Hedman L, Kainu A, et al. Reference values for spirometry - report from the Obstructive Lung Disease in Northern Sweden studies. Eur Clin Respir J. 2015;2:26375.CrossRef
27.
Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular Comorbidity in COPD Systematic Literature Review. Chest. 2013;144(4):1163–78.CrossRefPubMed
28.
Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010;7(1):5–10.CrossRefPubMed
29.
Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax. 2005;60(10):842–7.PubMedCentralCrossRefPubMed
30.
Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest. 2009;135(1):102–7.CrossRefPubMed
31.
Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.PubMedCentralCrossRefPubMed
32.
Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring Jr E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63–70.CrossRefPubMed
33.
Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(6):513–20.CrossRefPubMed
34.
Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pepin JL. Arterial stiffness in COPD. Chest. 2014;145(4):861–75.CrossRefPubMed
35.
Qvist L, Nilsson U, Johansson V, Larsson K, Rönmark E, Langrish J, et al. Central arterial stiffness is increased among subjects with severe and very severe COPD - report from a population based cohort-study. Eur Clin Respir J. 2015;2:27023.CrossRef
36.
Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014;69(1):80–1.CrossRefPubMed
37.
Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–92.CrossRefPubMed
38.
Eriksson B, Lindberg A, Mullerova H, Ronmark E, Lundback B. Association of heart diseases with COPD and restrictive lung function--results from a population survey. Respir Med. 2013;107(1):98–106.CrossRefPubMed
39.
Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096–103.CrossRefPubMed
40.
Shah A, Wagner GS, Green CL, Crater SW, Sawchak ST, Wildermann NM, et al. Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of nonocclusive etiologies. Am J Cardiol. 1997;80(4):512–3.CrossRefPubMed
41.
Michael MA, El Masry H, Khan BR, Das MK. Electrocardiographic signs of remote myocardial infarction. Prog Cardiovasc Dis. 2007;50(3):198–208.CrossRefPubMed
42.
Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2004;23(6):932–46.CrossRef
Metadata
Title
Ischemic heart disease among subjects with and without chronic obstructive pulmonary disease – ECG-findings in a population-based cohort study
Authors
Ulf Nilsson
Bengt Johansson
Berne Eriksson
Anders Blomberg
Bo Lundbäck
Anne Lindberg
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2015
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-015-0149-1

Other articles of this Issue 1/2015

BMC Pulmonary Medicine 1/2015 Go to the issue

Research article

Sudden death in young persons with uncontrolled asthma - a nationwide cohort study in Denmark

Research article

BMI, waist circumference at 8 and 12 years of age and FVC and FEV1 at 12 years of age; the PIAMA birth cohort study

Research article

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis

Research article

Clinical impact of high-attenuation and cystic areas on computed tomography in fibrotic idiopathic interstitial pneumonias

Research article

Ventilator-associated Pneumonia caused by commensal oropharyngeal Flora: a retrospective Analysis of a prospectively collected Database

Research article

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits